Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura in Children with Gastrointestinal Involvement

What this Trial Is About

IgA vasculitis is a condition that commonly affects children, particularly in Asian countries, and can cause serious abdominal problems like bleeding, pancreatitis, appendicitis, and intestinal intussusception. Delayed diagnosis may lead to severe complications or fatal outcomes. This trial aims to evaluate and compare treatment strategies for children with severe abdominal symptoms caused by IgA vasculitis, focusing on cost-effectiveness and clinical results. It is a multi-center, randomized, and controlled prospective study conducted in three children's medical centers in Shanghai. Participants will be randomly assigned to one of two treatment groups: one group receives methylprednisolone pulse therapy (15-30 mg/kg per day) for three days followed by oral prednisolone (2 mg/kg per day), while the other group receives intravenous immunoglobulin (IVIG) at 2 g/kg along with oral prednisolone at 2 mg/kg per day. If abdominal pain persists after three days, the treatment may switch to the alternate therapy. Supportive treatments such as omeprazole and low molecular weight heparin calcium are also provided. Blood purification treatment will be considered if both primary therapies fail to relieve symptoms. During the study, participants will be monitored for abdominal pain relief at 3 and 7 days after treatment, medication side effects, infection, hypertension, ocular hypertension, steroid-related diabetes, and hospital stay length. Researchers will also evaluate food tolerance, fasting duration, and treatment costs. The total participation duration includes follow-up assessments up to 4 weeks after treatment to track these outcomes and assess the safety and effectiveness of the treatment strategies.

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura